List view / Grid view

Dr Philipp Jost (scientific founder and Managing Director - Cycuria Therapeutics)

 

article

Targeting inflammatory cell death to tackle relapse in AML

Relapse in acute myeloid leukaemia is driven by malignant cells…

22 January 2026 | By

Relapse in acute myeloid leukaemia is driven by malignant cells that resist standard treatment. A synthetic cytokine approach in development targets inflammatory cell death pathways to suppress leukaemic cells while preserving healthy haematopoiesis.